Sarah P. Psutka, MD, MSc

“This is another therapeutic that adds to UroGen [profile] as a potential treatment that could be used to preserve kidneys while treating low grade upper tract urothelial carcinoma going forward,” says Sarah P. Psutka, MD, MSc.

“With the Expanded Access Program, it is an opportunity for patients to receive the drug in real-world practice,” says Sarah P. Psutka, MD, MSc.

“There was a wonderful breadth of discussion of some of the key questions that exist within management of bladder cancer right now,” says Sarah P. Psutka, MD, MSc.